These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 28427759)
1. Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population. Adehin A; Bolaji OO; Kennedy MA Drug Metab Pharmacokinet; 2017 Jun; 32(3):189-191. PubMed ID: 28427759 [TBL] [Abstract][Full Text] [Related]
2. Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients? Adehin A; Adeagbo BA; Kennedy MA; Bolaji OO; Olugbade TA; Bolarinwa RA; Durosinmi MA Leuk Lymphoma; 2019 Jan; 60(1):216-221. PubMed ID: 29741432 [TBL] [Abstract][Full Text] [Related]
3. Interethnic differences of cytochrome P450 gene polymorphisms may influence outcome of taxane therapy in Roma and Hungarian populations. Szalai R; Ganczer A; Magyari L; Matyas P; Bene J; Melegh B Drug Metab Pharmacokinet; 2015 Dec; 30(6):453-6. PubMed ID: 26507668 [TBL] [Abstract][Full Text] [Related]
4. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer. Gréen H; Khan MS; Jakobsen-Falk I; Åvall-Lundqvist E; Peterson C J Pharm Sci; 2011 Oct; 100(10):4205-9. PubMed ID: 21702053 [TBL] [Abstract][Full Text] [Related]
5. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241 [TBL] [Abstract][Full Text] [Related]
6. Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals. Yin SJ; Qi HM; Wang X; Zhang P; Lu Y; Wei MJ; Li P; Qi GZ; Lou YQ; Lu C; Zhang GL Pharmacogenet Genomics; 2017 Apr; 27(4):125-134. PubMed ID: 28099407 [TBL] [Abstract][Full Text] [Related]
7. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia. Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203 [TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876 [TBL] [Abstract][Full Text] [Related]
9. Clinical Probe of Cyp2C8*2 Mutants in a Malaria Hyperendemic Zone: Evidence from North-Central, Nigeria. Shittu O; Opeyemi OA; Omotesho OB; Fakayode O; Asogwa N; Adeniyi OM; Fatoba IM; Salawu KM; Ajibaye O; Babamale OA; Iyiola OA; Aremu OI Acta Medica (Hradec Kralove); 2020; 63(3):119-123. PubMed ID: 33002398 [TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Khan MS; Barratt DT; Somogyi AA Xenobiotica; 2016; 46(3):278-87. PubMed ID: 26161459 [TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Hilli J; Rane A; Lundgren S; Bertilsson L; Laine K Fundam Clin Pharmacol; 2007 Aug; 21(4):379-86. PubMed ID: 17635176 [TBL] [Abstract][Full Text] [Related]
12. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation. Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316 [TBL] [Abstract][Full Text] [Related]
13. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978 [TBL] [Abstract][Full Text] [Related]
14. Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants. Hiratsuka M Biol Pharm Bull; 2016; 39(11):1748-1759. PubMed ID: 27803446 [TBL] [Abstract][Full Text] [Related]
16. [Polymorphisms of CYP3A5 gene in acute leukemia patients and their role in chemotherapy and prognosis]. Shen LJ; Chen FY; Wang T; Wang HR; Zhong JH; Han JY; Ouyang RR Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):26-30. PubMed ID: 18315894 [TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of CYP2C8 in the Czech Republic. Pechandova K; Buzkova H; Matouskova O; Perlik F; Slanar O Genet Test Mol Biomarkers; 2012 Jul; 16(7):812-6. PubMed ID: 22313047 [TBL] [Abstract][Full Text] [Related]
18. Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer. Alcazar-González GA; Calderón-Garcidueñas AL; Garza-Rodríguez ML; Rubio-Hernández G; Escorza-Treviño S; Olano-Martin E; Cerda-Flores RM; Castruita-Avila AL; González-Guerrero JF; le Brun S; Simon-Buela L; Barrera-Saldaña HA Pharmacogenomics; 2013 Oct; 14(13):1583-92. PubMed ID: 24088129 [TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis. Zhou S; Xiang Q; Mu G; Ma L; Chen S; Xie Q; Zhang Z; Cui Y Curr Drug Metab; 2019; 20(4):266-274. PubMed ID: 30636597 [TBL] [Abstract][Full Text] [Related]